Related references
Note: Only part of the references are listed.Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
John C. Byrd et al.
BLOOD (2020)
Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib
David Wanner et al.
ANNALS OF HEMATOLOGY (2019)
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
Antonio Cuneo et al.
HEMATOLOGICAL ONCOLOGY (2019)
The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
Stalin Chellappa et al.
JOURNAL OF IMMUNOLOGY (2019)
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group
Anne Quinquenel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network
Eleanor Kane et al.
CANCER EPIDEMIOLOGY (2019)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P. Sharman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece
Maria Dimou et al.
LEUKEMIA & LYMPHOMA (2019)
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignanciesA single institution experience and a review of literature
Hira Shaikh et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment
Quentin A. Hill et al.
BLOOD ADVANCES (2019)
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives
Marta Coscia et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2019)
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
Iris de Weerdt et al.
BLOOD ADVANCES (2019)
Refractory Autoimmune Cytopenias Treated With Venetoclax
Max J. Gordon et al.
HEMASPHERE (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections
Talal Hilal et al.
BLOOD REVIEWS (2018)
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Matthew S. Davids et al.
CLINICAL CANCER RESEARCH (2018)
The clinical characteristics and therapy response of patients with acquired pure red cell aplasia
Rong Fu et al.
HEMATOLOGY (2018)
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chronic lymphocytic leukaemia
Michael Hallek et al.
LANCET (2018)
Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy
Jan A. Burger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre
Paul J. Hampel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Evidence-based management of immune thrombocytopenia: ASH guideline update
Cindy E. Neunert et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)
The diagnosis and management of primary autoimmune haemolytic anaemia
Quentin A. Hill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients
Andrea Visentin et al.
EUROPEAN JOURNAL OF CANCER (2017)
Clinical and serological autoimmune complications in chronic lymphocytic leukemia
Cengiz Demir et al.
WIENER KLINISCHE WOCHENSCHRIFT (2017)
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
M. Montillo et al.
BLOOD CANCER JOURNAL (2017)
A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
Mazie Tsang et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p)
Marcelo Pitombeira de Lacerda et al.
ANNALS OF HEMATOLOGY (2017)
Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial
Sigbjorn Berentsen et al.
BLOOD (2017)
Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia
Anthony R. Mato et al.
BLOOD (2016)
Guidelines for the diagnosis and management of adult aplastic anaemia
Sally B. Killick et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia
Tom G. Rider et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia
K. A. Rogers et al.
LEUKEMIA (2016)
Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature
Stefano Molica et al.
LEUKEMIA & LYMPHOMA (2016)
Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia
L. Falchi et al.
ANNALS OF ONCOLOGY (2016)
The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia
Justyna Rybka et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2016)
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Benjamin L. Lampson et al.
BLOOD (2016)
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
Candida Vitale et al.
HAEMATOLOGICA (2016)
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer et al.
LANCET ONCOLOGY (2016)
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion
Francesco Cavazzini et al.
LEUKEMIA & LYMPHOMA (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Secondary autoimmune cytopenias in chronic lymphocytic leukemia
Kerry A. Rogers et al.
SEMINARS IN ONCOLOGY (2016)
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
Stefania Fiorcari et al.
ONCOTARGET (2016)
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
Candida Vitale et al.
HAEMATOLOGICA (2016)
Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)
Anne Quinquenel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia
Rosanne St Bernard et al.
ANNALS OF HEMATOLOGY (2015)
Perturbation of the normal immune system in patients with CLL
Francesco Forconi et al.
BLOOD (2015)
A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2015)
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia
Sudhir Manda et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia
Mona Lisa Alattar et al.
LEUKEMIA & LYMPHOMA (2015)
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E. Coutre et al.
LEUKEMIA & LYMPHOMA (2015)
Inhibition of PI3Kδ Reduces Kidney Infiltration by Macrophages and Ameliorates Systemic Lupus in the Mouse
Abel Suarez-Fueyo et al.
JOURNAL OF IMMUNOLOGY (2014)
Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression
Wilma Barcellini et al.
LEUKEMIA & LYMPHOMA (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibutinib-Associated Autoimmune Hemolytic Anemia in CLL
Jacob Hodskins et al.
BLOOD (2014)
Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases
Lev Shvidel et al.
ANNALS OF HEMATOLOGY (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia
Neta Goldschmidt et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Specific inhibition of PI3K p110δ inhibits CSF-1-induced macrophage spreading and invasive capacity
Kellie A. Mouchemore et al.
FEBS JOURNAL (2013)
Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias
Deepesh P. Lad et al.
LEUKEMIA & LYMPHOMA (2013)
Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia
Gianluigi Reda et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders
Tadeusz Robak et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Pure Red Cell Aplasia and Lymphoproliferative Disorders: An Infrequent Association
Efthymia Vlachaki et al.
SCIENTIFIC WORLD JOURNAL (2012)
Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus
Jack Hutcheson et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Unusual Autoimmune Nonhematologic Complications in Chronic Lymphocytic Leukemia
Moonjung Jung et al.
Clinical Lymphoma Myeloma & Leukemia (2011)
Diagnosis of Autoimmune Neutropenia by Neutrophil-bound IgG and IgM Antibodies
Taichi Ito et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2011)
Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia
J. Rossignol et al.
LEUKEMIA (2011)
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease
Giovanni D'Arena et al.
LEUKEMIA RESEARCH (2011)
Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL)
Clive S. Zent et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches
Vicki A. Morrison
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance
Carol Moreno et al.
BLOOD (2010)
Autoimmune haemolytic anaemia in patients with chronic lymphocytic eukaemia treated with 2-chlorodeoxyadenosine (cladribine)
T. Robak et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status
Carlo Visco et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation
Daniela Rozkova et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone
Deborah A. Bowen et al.
LEUKEMIA & LYMPHOMA (2010)
Late-Onset Neutropenia After Rituximab Treatment Case Series and Comprehensive Review of the Literature
Ofir Wolach et al.
MEDICINE (2010)
T-cell function in chronic lymphocytic leukaemia
John C. Riches et al.
SEMINARS IN CANCER BIOLOGY (2010)
The Bcl-2 Family Antagonist ABT-737 Significantly Inhibits Multiple Animal Models of Autoimmunity
Philip D. Bardwell et al.
JOURNAL OF IMMUNOLOGY (2009)
A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia
Matthew Kaufman et al.
LEUKEMIA & LYMPHOMA (2009)
Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis
Clive S. Zent et al.
LEUKEMIA & LYMPHOMA (2009)
The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma
Clive S. Zent et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3:: Possible role as initiators of autoimmune hemolytic anemia
Jeremias Galletti et al.
JOURNAL OF IMMUNOLOGY (2008)
Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia
Aaron Viny et al.
LEUKEMIA & LYMPHOMA (2008)
Disease-Specific Complications of Chronic Lymphocytic Leukemia
C. Dearden
Hematology-American Society of Hematology Education Program (2008)
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
Claire Dearden et al.
BLOOD (2008)
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia
Carlo Visco et al.
BLOOD (2008)
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors
Gautam Borthakur et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells
Cindy Grandjenette et al.
HAEMATOLOGICA (2007)
The p110δ isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells
Klaus Okkenhaug et al.
JOURNAL OF IMMUNOLOGY (2006)
Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries
O Landgren et al.
BLOOD (2006)
Autoimmune complications of chronic lymphocytic leukemia
TJ Hamblin
SEMINARS IN ONCOLOGY (2006)
Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells
AM Hall et al.
BLOOD (2005)
Primary and secondary autoimmune neutropenia
F Capsoni et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Cutting edge:: Differential roles for phosphoinositide 3-kinases, p110γ and p110δ, in lymphocyte chemotaxis and homing
K Reif et al.
JOURNAL OF IMMUNOLOGY (2004)
Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma
MJ Kyasa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2003)
Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes
RS Go et al.
BLOOD (2001)
Autoimmune thrombocytopenia: A complication of fludarabine therapy in lymphoproliferative disorders
M Leach et al.
CLINICAL AND LABORATORY HAEMATOLOGY (2000)
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features
FR Mauro et al.
BLOOD (2000)